Consumer Advocacy Groups, Pharmaceutical Companies Debate Three-Year Marketing Exclusivity Period Awarded By FDA For Plan B
Main Category: Cancer / OncologyAlso Included In: Women's Health / Gynecology; Pediatrics / Children's Health
Article Date: 15 Nov 2006 - 17:00 PDT
| Patient / Public: | ![]() | |
| Healthcare Prof: | ![]() |
Consumer advocates and drug companies are debating FDA's decision to grant Barr Pharmaceuticals three years of regulatory exclusivity for its emergency contraceptive Plan B, which can prevent pregnancy if taken up to 72 hours after sexual intercourse, the Boston Globe reports. In exchange for exclusivity -- in which the drug will receive no generic competition for a certain period of time -- Barr must conduct a series of studies to determine how consumers use the product and how they understand the new label. Melissa Dunn, a spokesperson for GlaxoSmithKline Consumer Healthcare, said exclusivity provides "some incentive for innovation," adding, "It's really for companies who are doing all of the background research, investing the [research and development] dollars, and time and efforts into developing a product to give them some protection for a period of time." GSK received three years of exclusivity for over-the-counter sales of the smoking cessation drug Nicorette. Sidney Wolfe, director of the Health Research Group at Public Citizen, said the exclusivity means that consumers will have to pay more for the drug than they should, adding that pharmaceutical companies "should get some advantage for" their research, "but it seems like three years is on the long side." Democratic lawmakers, who will hold the majority in the 110th Congress, have said they will seek some restrictions in the methods drug makers use to keep generic competition off the market (Boston Globe, 11/13).
"Reprinted with permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation . © 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.
Visit our cancer / oncology section for the latest news on this subject.
MLA
14 Feb. 2012. <http://www.medicalnewstoday.com/releases/56547.php>
APA
http://www.medicalnewstoday.com/releases/56547.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




